SIOUX FALLS, S.D.--(BUSINESS WIRE)--pharmaCline today announced a poster presentation at the Fall 2013 Symposium on Advanced Wound Care, September 27-29, 2013, in Las Vegas, NV. The poster presentation, entitled "An In Vitro Anti-Bacterial Side-by-Side Comparison Between a Novel OTC First Aid Antibiotic Ointment and Several Leading Topical and Prescription Antibiotics," discussed the findings from a third-party study overseen by the South Dakota School of Pharmacy that measured the comparative efficacy of Diabecline®, pharmaCline’s novel over-the-counter (OTC) tetracycline HCl First Aid Antibiotic, and 6 other commercially available prescription and OTC first aid antibiotic ointments.
Diabecline® first aid antibiotic ointment was shown to have greater than 99% efficacy over 24 hours against 6 common bacteria in vitro including Methicillin-resistant Staphylococcus aureus (MRSA). Diabecline® was shown to be either comparable or superior in killing Escherichia coli (E. coli), Pseudomonas aeruginosa, Coagulase-negative Staphylococcus aureus (CNSA), Methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-susceptible Staphylococcus aureus (MSSA), and Mupirocin-resistant Staphylococcus aureus (MuRSA), compared to the other 6 topical first aid antibiotic products studied.
Diabecline® first aid antibiotic ointment employs pharmaCline’s proprietary drug delivery technology, Site Specific Penetration Technology, or SSPT®. SSPT® serves as an active pharmaceutical ingredient (API) carrier, and it is believed that it releasably binds to the API, transporting it through the pathogen cell wall, effectively killing the bacteria. It is believed that the SSPT® carrier also affects the water activity level in the bacteria, producing a shock to the normal survival processes of the bacteria. These two activities produce both a pharmaceutical and a mechanical kill.
pharmaCline plans to launch Diabecline® nationwide to retail pharmacies and long-term care facilities during the first quarter of 2014. Additional OTC and prescription products utilizing pharmaCline’s proprietary SSPT® drug delivery technology are in development.
pharmaCline has received numerous innovation, product, and business awards for its ground-breaking wound care product, Diabecline®, and its proprietary Site Specific Penetration Technology, SSPT®, which restores to effective use old and well known classes of active pharmaceuticals. pharmaCline is seeking strategic partners to enhance the health and productivity of people worldwide. For additional information about partnering with or investing in pharmaCline, visit www.pharmacline.com.